



**MYDECINE™**  
M E D I C I N E E V O L V E D

### **Mydecine to Participate in Upcoming Investor Events in August 2021**

**DENVER, July 28, 2021** — [Mydecine Innovations Group](#) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will participate in two upcoming investor events in August 2021:

- BTIG Biotechnology Conference to be held virtually on August 9-10, 2021. Mr. Bartch will present on Tuesday, August 10th at 3:00 p.m. ET.
- Canaccord Genuity’s 41st Annual Growth Conference to be held virtually on August 10-12, 2021. Mr. Bartch will present on Tuesday, August 10th at 10:00 a.m. ET.

For more information about the conferences, or to schedule a one-on-one meeting with Mydecine management, please contact your appropriate BTIG or Canaccord representative directly, or send an email to KCSA Strategic Communications at [MYCO@kcsa.com](mailto:MYCO@kcsa.com).

#### **About Mydecine Innovations Group**

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: <https://www.mydecine.com> and follow us on [Facebook](#), [Twitter](#), and [Instagram](#).

**For more information, please contact:**

**Media Contacts**

Anne Donohoe / Nick Opich  
KCSA Strategic Communications  
[myco@kcsa.com](mailto:myco@kcsa.com)  
1-212-896-1265 / 1-212-896-1206

**Investor Contacts**

Charles Lee, Investor Relations  
[corp@mydecineinc.com](mailto:corp@mydecineinc.com)  
1-720-277-9879

Allison Soss / Erika Kay  
KCSA Strategic Communications  
[myco@kcsa.com](mailto:myco@kcsa.com)  
1-212-896-1267

**On behalf of the Board of Directors:**

Joshua Barch, Chief Executive Officer  
[contact@mydecineinc.com](mailto:contact@mydecineinc.com)

**For further information about Mydecine Innovations Group, Inc., please visit the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) or visit the Company's website at [www.mydecine.com](http://www.mydecine.com).**

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management's current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

###